ADVA
12.5.2020 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it is playing a key role in a unique research initiative extending post-quantum security to VPN networks. Leveraging the ADVA FSP 150 with ConnectGuard™ Ethernet encryption, the Quantum-Secure VPN Modules and Operation Modes (QuaSiModO) project is testing new quantum-resistant algorithms in the packet domain. It will develop viable security solutions that can protect Layer 2 and 3 data against all forms of cyberattack, including those from quantum computers. By participating in the initiative, ADVA is extending its industry-leading work with quantum-safe cryptography in optical transport to higher network layers. Other QuaSiModO project partners are the Fraunhofer Institute of Applied and Integrated Security, the Ludwig Maximilian University of Munich and genua GmbH.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200512005043/en/
“As part of the QuaSiModO project, we’re continuing to drive innovation in future-proof cryptography. This initiative extends comprehensive post-quantum security to VPNs and enables businesses and government institutions to protect their data from tomorrow’s attacks,” said Jörg-Peter Elbers, SVP, advanced technology, ADVA. “Together with our partners, we’re ensuring that network security technology doesn’t fall behind in the computing power race. Our role in the project combines our experience with transport layer post-quantum security and our proven expertise when it comes to encrypting Carrier Ethernet connectivity. We’re helping to create a solution able to protect packet services today and ready to be upgraded later to comply with emerging specifications from standards bodies such as the USA’s National Institute of Standards and Technology.”
Quantum computers of sufficient size and reliability could arrive within the next 10 to 15 years. This may mean that today’s widely applied data protection technologies will no longer be sufficient. What’s more, sensitive and valuable information may be at risk right now from harvesting attacks, with attackers storing information today to decrypt it as soon as large quantum computers are available. Funded by the German Federal Ministry of Education and Research, the QuaSiModO project is researching, testing and helping to standardize quantum-resistant algorithms in VPN implementations. It aims to extend existing IPSec and MACsec communication protocols with quantum-resistant procedures and support the development of complete solutions. The initiative is utilizing ADVA FSP 150 edge devices with ConnectGuard™ Ethernet encryption technology based on an enhanced version of MACsec. The solution provides high throughput and low-latency performance as it encrypts across multiple domains and service provider networks.
“When quantum computers emerge, they’ll be able to quickly crack complex problems that would take today’s most powerful supercomputers many years to solve. That’s why enterprises, governments and communication service providers are looking to leverage security technology built on quantum-safe algorithms,” commented Alexander von Gernler, head of research, genua GmbH. “For a decade, we’ve been focused on the threat posed by large quantum computers, and much of our work in recent years has been about developing practical quantum-resistant signatures and key establishment protocols. Now, we’re leading the QuaSiModO consortium, working with ADVA and the other partners to bring post-quantum security to network Layers 2 and 3, and deliver the robust future-proof protection that classical encryption technologies simply can’t.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005043/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom